EXTON, Pa.--(EON: Enhanced Online News)--Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing innovative products for skin diseases and conditions, today announced the company was honored with a Partners in Progress Award from the Dystrophic Epidermolysis Bullosa Research Association of America (DEBRA). The award recognizes the company’s recent work developing potential therapies for those with epidermolysis bullosa (EB), a rare, genetic, connective tissue disorder for which there is no treatment or cure. David Pernock, Chairman and CEO of Fibrocell Science, accepted the award during the 15th Annual DEBRA of America Benefit at The Museum of Modern Art in New York City on October 24, 2013.
“We are honored to be recognized by DEBRA for exploring the use of genetically-modified, autologous fibroblast cells for recessive dystrophic epidermolysis bullosa (RDEB), the most severe form of EB”
“We are honored to be recognized by DEBRA for exploring the use of genetically-modified, autologous fibroblast cells for recessive dystrophic epidermolysis bullosa (RDEB), the most severe form of EB,” said Mr. Pernock. “This work is part of our Exclusive Channel Collaboration with Intrexon Corporation, a leader in synthetic biology, to develop a treatment for RDEB. Our hope is that our work will help those suffering from this painful and debilitating genetic blistering disorder.”
The DEBRA of America Benefit marks the start of the annual National Epidermolysis Bullosa Awareness Week—October 25 through October 31—which was created to increase awareness of EB, to promote the need for a cure and to spur advocacy initiatives on behalf of those suffering with the emotional, financial, and physical burden of the disease.
“I am very excited by the innovative science that Fibrocell is embarking on to help those that suffer from EB,” said Brett Kopelan, Executive Director of DEBRA of America. “As a father of a recessive dystrophic little girl and as the Executive Director, I thank Mr. Pernock and his team for pursing therapy options for this orphan disease.”
About Epidermolysis Bullosa (EB)
Epidermolysis Bullosa (EB) is a rare, genetic, connective tissue disorder. There are many genetic and symptomatic variations of EB, but all share the prominent symptom of extremely fragile skin that blisters and tears from minor friction or trauma. Internal organs and bodily systems can also be seriously affected by the disease. EB is always painful, is often pervasive and debilitating, and is in some cases lethal before the age of 30. EB affects 1 out of every 20,000 live births and those born with it are often called ‘Butterfly Children’ because, as the analogy goes, their skin is as fragile as the wings of a butterfly. There is no treatment or cure. Daily wound care, pain management, and protective bandaging are the only options available. Learn more at: debra.org/whatiseb.
About DEBRA of America
The Dystrophic Epidermolysis Bullosa Research Association of America was founded in 1980 and is the only national nonprofit dedicated to funding research for treatments and a cure, while providing supportive services and programs for those who suffer from the rare and painful genetic disorder, “Epidermolysis Bullosa (EB) – The Worst Disease You've Never Heard Of.™”
About Fibrocell Science, Inc.
Fibrocell Science, Inc. (NYSE MKT:FCSC) is an autologous cell therapy company primarily focused on developing innovative products for skin diseases and conditions. Fibrocell
Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well as its innovative cellular processing technology and manufacturing excellence. For additional information, please visit www.fibrocellscience.com.
About Intrexon Corporation
Intrexon Corporation (NYSE:XON) is a leader in synthetic biology focused on collaborating with companies in Health, Food, Energy and the Environment to create biologically-based products that improve the quality of life and the health of the planet. Through the company's proprietary UltraVector® platform, Intrexon provides its partners with industrial-scale design and development of complex biological systems. The UltraVector® platform delivers unprecedented control over the quality, function, and performance of living cells. We call our synthetic biology approach and integrated technologies Better DNA®, and we invite you to discover more at www.dna.com.
Safe Harbor Statement
Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.